This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Murray Epstein, MD

Arch Intern Med. 1991;151(12):2361-2364.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The kidney disease of diabetes mellitus (ie, diabetic nephropathy) is a clinical syndrome characterized by albuminuria, hypertension, and inexorably progressive renal insufficiency.^1-3 The magnitude of this problem can be gauged by the realization that approximately 30% of new cases of end-stage renal disease in the United States are attributable to diabetic nephropathy, making it one of the two most common causes of renal failure in this country.⁴ The role of pharmacologic interventions to ameliorate or retard the progression of such diabetic nephropathy has not been established.

Over the past several years, angiotensin converting enzyme (ACE) inhibitors have been advocated as being advantageous in patients with diabetic nephropathy. The observations from Brenner's laboratory^5-7 have provided a theoretic framework for therapeutic interventions with an ACE inhibitor in patients with diabetes mellitus. These theoretical observations, coupled with the relative paucity of side effects of these agents, have eventuated in an . . . [Full Text PDF of this Article]

Author Affiliations
Nephrology Section Department of Veterans Affairs Medical Center 1201 NW 16th St Miami, FL 33125

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?